Compare Organon & Co. Common Stock (OGN) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Banco Santander SA — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Banco Santander SA trades at $13.59 (market cap $196.48B). The key difference: Banco Santander SA is far larger — about 54.3× Organon & Co. Common Stock's market cap, and Banco Santander SA pays the higher dividend (2.14%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Banco Santander SA for 55 Days on average.
| OGN | SAN | |
|---|---|---|
Market Cap | $3.62B | $196.48B |
Volume | 2,892,999 | 9,811,951 |
Sector | Health | Financials |
52-Week High | $13.81 | $15.05 |
52-Week Low | $5.70 | $9.65 |
Typical Hold Time | 0 Days | 55 Days |
Enterprise Value | $11.04B | $362.68B |
Dividend Yield | 0.58% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Banco Santander (SAN) trades at $13.41, down 0.52% on the day, with a bearish technical signal from moving averages and a mixed earnings history including a Q1 2026 beat. The company maintains strong profitability with a 26.25% net income margin and a 16.07% ROE, supported by record profits highlighted in recent earnings calls. Recent developments include the completion of the Webster acquisition, expanding its U.S. presence, and a dividend payment scheduled for November 2026.
The outlook is cautiously optimistic with analyst consensus at 'Moderate Buy' (64% buy ratings), but risks include declining cash flows from operations and rising debt-to-asset ratios. Revenue growth is projected to reach $61.9B in 2026, though net cash flow turned negative in 2024-2025, signaling potential liquidity pressures. Investors should weigh strong profitability against financial leverage and integration risks from acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
